Personalized voriconazole dosing for blood cancer patients
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests whether using a genetic test to set the first dose of voriconazole (an antifungal medicine) can make treatment safer and more effective for people with blood cancers. It aims to reduce side effects and improve how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with a blood cancer (like leukemia or lymphoma).
- You are being treated at the Grenoble Alps University Hospital's hematology department or day hospital.
- You are about to start voriconazole, either to prevent or treat a fungal infection.
- You agree to a genetic test (CYP2C19) to help guide your dose.
- You are not taking certain other medicines that could interfere with voriconazole (like valproic acid, phenytoin, carbamazepine, or rifampicin).
- You are not pregnant, breastfeeding, or in a situation that prevents you from giving consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if using genetic information can help doctors choose the right dose of the antifungal drug voriconazole. It aims to improve treatment and reduce side effects for people with fungal infections.
This study monitors how the antifungal drug isavuconazole works in children's bodies. It aims to find the right dose for treating serious fungal infections.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
This study tests a medicine called isavuconazole, which is used to treat serious fungal infections. It aims to see if it is safe and works well in very sick patients in the intensive care unit (ICU).
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
Hear when a new Aspergillosis Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.